<unk>  (TDTA) belongs to a class of chemotherapy drugs known as High Specificity Anticancer Agents. This is a process for manufacturing and administering chemotherapy drugs in a nontoxic, proto-drug form. Then, after a<unk><unk>  to allow for concentration in the target cancer or invasive tissues or cells, the non-toxic drug is then modified by an<unk>  drug to selectively provide<unk>  levels of a pharmacologically active agent to the target issue. This minimizes the<unk> ity to healthy cells, reducing the adverse side-effects of chemotherapy. This idea was first proposed by Dr. Evan Harris Walker in 1980.
Time delay toxin activation
Broad-spectrum therapeutic
Virtually safe dose
Antihemorrhagic
Eradication of infectious diseases
Correlates of immunity
Lasers in cancer treatment
Severe cutaneous adverse reactions